Gamma-Aminobutyric Acid (GABA)

Migration, Crosslink

📖

Gamma-Aminobutyric Acid (GABA)

active

wiki page Created: 2026-04-02T07:20:05 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-entities-gaba

📖 Wiki Page

entity2056 wordssynced 2026-04-02

Introduction

Gamma Aminobutyric Acid (Gaba) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

flowchart TD entities_gaba["Gamma-Aminobutyric Acid GABA"] style entities_gaba fill:#4fc3f7,stroke:#333,color:#000 entities_gaba_0["Synthesis and Metabolism"] entities_gaba -->|"includes"| entities_gaba_0 style entities_gaba_0 fill:#81c784,stroke:#333,color:#000 entities_gaba_1["Biosynthesis"] entities_gaba -->|"includes"| entities_gaba_1 style entities_gaba_1 fill:#ef5350,stroke:#333,color:#000 entities_gaba_2["Vesicular Transport and Release"] entities_gaba -->|"includes"| entities_gaba_2 style entities_gaba_2 fill:#ffd54f,stroke:#333,color:#000 entities_gaba_3["Reuptake and Degradation"] entities_gaba -->|"includes"| entities_gaba_3 style entities_gaba_3 fill:#ce93d8,stroke:#333,color:#000 entities_gaba_4["GABA Receptors"] entities_gaba -->|"includes"| entities_gaba_4 style entities_gaba_4 fill:#4fc3f7,stroke:#333,color:#000 entities_gaba_5["GABA_A Receptors Ionotropic"] entities_gaba -->|"includes"| entities_gaba_5 style entities_gaba_5 fill:#81c784,stroke:#333,color:#000

...

Introduction

Gamma Aminobutyric Acid (Gaba) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Mermaid diagram (expand to render)

Gamma-aminobutyric acid (GABA) is the principal inhibitory neurotransmitter in the mammalian central nervous system (CNS), counterbalancing excitatory [glutamate](/entities/glutamate) signaling to maintain the excitation–inhibition (E/I) balance essential for normal brain function. Approximately 20–30% of all CNS [neurons](/entities/neurons) are GABAergic, including diverse populations of interneurons that regulate cortical and subcortical circuit activity [@siegel1999]. [@mody2021]

Disruption of GABAergic neurotransmission is increasingly recognized as a key contributor to [neurodegenerative diseases, including [alzheimers](/diseases/alzheimers-disease), [huntington-pathway](/mechanisms/huntington-pathway), [parkinsons](/diseases/parkinsons-disease), and [als](/diseases/amyotrophic-lateral-sclerosis). In [alzheimers](/diseases/alzheimers-disease), the selective vulnerability of specific GABAergic interneuron subtypes—particularly somatostatin-positive (SST) interneurons—leads to network hyperexcitability, impaired oscillatory rhythms, and cognitive decline. Understanding the roles of GABA in health and disease has opened new avenues for therapeutic intervention in neurodegeneration [@mody2021]. [@schwarcz2021]

Synthesis and Metabolism

Biosynthesis

GABA is synthesized from [glutamate](/entities/glutamate) by the enzyme glutamic acid decarboxylase (GAD), which exists in two isoforms: [@jo2014]

GAD67 (GAD1): A 67-kDa cytoplasmic enzyme constitutively active throughout the cell; responsible for basal GABA production
GAD65 (GAD2): A 65-kDa enzyme localized to synaptic terminals; activated on demand during neurotransmission and responsible for vesicular GABA pools

Both GAD isoforms require pyridoxal 5′-phosphate (PLP, a vitamin B6 derivative) as a cofactor. Dysregulation of GAD expression and activity has been documented in multiple neurodegenerative diseases, with reduced GAD67 mRNA levels observed in the [hippocampus](/brain-regions/hippocampus) and [cortex](/brain-regions/cortex) of [alzheimers](/diseases/alzheimers-disease) patients [@schwarcz2021]. [@rudolph2004]

Vesicular Transport and Release

After synthesis, GABA is loaded into synaptic vesicles by the vesicular GABA transporter (VGAT/SLC32A1), also known as vesicular inhibitory amino acid transporter (VIAAT). Upon arrival of an action potential and calcium influx, GABA is released into the synaptic cleft, where it binds to postsynaptic and presynaptic receptors. [@cryan2021]

Reuptake and Degradation

GABA is cleared from the synaptic cleft primarily by membrane-bound GABA transporters (GATs), of which four subtypes exist (GAT-1 to GAT-3, and BGT-1). GAT-1, expressed on both [neurons](/entities/neurons) and [astrocytes](/cell-types/astrocytes), is the most abundant. Tiagabine, a GAT-1 inhibitor, is used clinically as an antiepileptic drug. [@bhatt2025]

Once taken up by [astrocytes](/cell-types/astrocytes), GABA is catabolized by GABA transaminase (GABA-T) to succinic semialdehyde, which is further converted to succinate and enters the tricarboxylic acid (TCA) cycle. This metabolic pathway, known as the GABA shunt, links inhibitory neurotransmission to cellular energy metabolism. [@huh2022]

Notably, reactive [astrocytes](/cell-types/astrocytes) in [alzheimers](/diseases/alzheimers-disease) overexpress monoamine oxidase B (MAO-B), which produces GABA through an alternative pathway involving putrescine degradation. This astrocytic GABA release has been shown to tonically inhibit surrounding [neurons](/entities/neurons), contributing to memory impairment in AD mouse models [@jo2014].

GABA Receptors

GABA exerts its effects through three receptor classes:

GABA_A Receptors (Ionotropic)

GABA_A receptors are ligand-gated chloride channels composed of pentameric subunit assemblies drawn from 19 subunit genes (α1–6, β1–3, γ1–3, δ, ε, θ, π, ρ1–3). The most common synaptic configuration is α1β2γ2, while extrasynaptic receptors (e.g., α5βγ2 or α4βδ) mediate tonic inhibition.

Key features in neurodegeneration:

α5-containing GABA_A receptors: Enriched in the [hippocampus](/brain-regions/hippocampus), these extrasynaptic receptors mediate tonic inhibition and have been implicated in cognitive deficits in AD. Inverse agonists at α5-GABA_A receptors have shown procognitive effects in preclinical AD models [@rudolph2004]
Loss of GABA_A receptor subunits: Postmortem studies of AD brains show selective loss of specific GABA_A receptor subunits (α1, α5, β3) in the [hippocampus](/brain-regions/hippocampus) and temporal [cortex](/brain-regions/cortex)
Benzodiazepine binding site: Modulated by benzodiazepines, barbiturates, and neurosteroids; the benzodiazepine binding site on GABA_A receptors (α/γ interface) is relatively preserved in AD, supporting continued clinical utility of these agents

GABA_B Receptors (Metabotropic)

GABA_B receptors are G protein-coupled receptors (Gi/Go) that form obligate heterodimers of GABA_B1 and GABA_B2 subunits. They mediate slow, prolonged inhibition by:

Activating potassium channels (postsynaptic hyperpolarization)
Inhibiting calcium channels (presynaptic reduction of neurotransmitter release)
Suppressing adenylyl cyclase activity

GABA_B receptors are implicated in multiple neurodegenerative conditions. In AD, GABA_B receptor dysfunction contributes to network hyperexcitability and has been proposed as a therapeutic target [@cryan2021]. Baclofen, a GABA_B agonist, has shown neuroprotective properties in preclinical models of neurodegeneration.

GABA_C Receptors

Now reclassified as ρ-containing GABA_A receptors, these are primarily expressed in the retina and have limited involvement in neurodegenerative disease.

GABAergic Interneurons in the Brain

GABAergic interneurons represent approximately 20% of cortical [neurons](/entities/neurons) and are classified into molecularly and functionally distinct subtypes:

Parvalbumin (PV) Interneurons

PV interneurons are fast-spiking cells that provide perisomatic inhibition to pyramidal [neurons](/entities/neurons), generating gamma oscillations (30–100 Hz) critical for working memory and attention. They include basket cells and chandelier (axo-axonic) cells. PV interneurons are ensheathed by perineuronal nets (PNNs), specialized extracellular matrix structures that provide neuroprotection.

In AD, PV interneurons show relative resilience compared to other interneuron subtypes, potentially due to PNN protection. However, PV interneuron hyperactivity in the subiculum has been shown to drive early amyloid pathology and cognitive deficits [@bhatt2025]. Compensatory neuroplasticity in PV interneurons may help maintain executive function in early disease stages [@huh2022].

Somatostatin (SST) Interneurons

SST interneurons target the dendrites of pyramidal [neurons](/entities/neurons), providing dendritic inhibition that modulates excitatory input integration and theta oscillations (4–12 Hz). They are the most vulnerable interneuron subtype in AD, exhibiting tau] inclusions, atrophy, and neuronal loss early in disease progression [@targa2022].

SST interneuron loss contributes to:

Impaired dendritic computation in pyramidal [neurons](/entities/neurons)
Disrupted theta oscillations in the [hippocampus](/brain-regions/hippocampus)
Disinhibition of cortical circuits, promoting hyperexcitability
Reduced somatostatin peptide levels, which normally enhance [neprilysin](/proteins/neprilysin)-mediated [amyloid-beta](/proteins/amyloid-beta) degradation

Vasoactive Intestinal Peptide (VIP) Interneurons

VIP interneurons are disinhibitory cells that primarily inhibit other interneurons (SST and PV cells), thereby modulating cortical gain and state-dependent processing. Their role in neurodegeneration is less well characterized but is an area of active investigation.

Neuropeptide Y (NPY) and Cholecystokinin (CCK) Interneurons

NPY-expressing interneurons overlap with SST-expressing populations and are reduced in AD [cortex](/brain-regions/cortex). CCK interneurons are basket cells that provide perisomatic inhibition at cannabinoid receptor type 1 (CB1)-expressing synapses.

Role in Neurodegenerative Diseases

Alzheimer's Disease

The relationship between GABAergic dysfunction and AD is multifaceted:

Excitation/Inhibition Imbalance: Loss of GABAergic interneurons and altered GABA receptor expression disrupts the E/I balance, producing network hyperexcitability. This manifests clinically as subclinical epileptiform activity, which occurs in 22–54% of AD patients and accelerates cognitive decline [@palop2010].

Oscillatory Disruption: Impaired gamma and theta oscillations due to interneuron dysfunction compromise memory encoding and retrieval. Gamma entrainment using 40 Hz sensory stimulation has emerged as a novel therapeutic approach, promoting [microglia](/cell-types/microglia)-mediated amyloid clearance and restoring neural oscillations [@iaccarino2016].

Huntington's Disease

[Huntington's disease](/diseases/huntingtons) (HD) is characterized by progressive loss of [medium spiny neurons](/cell-types/medium-spiny-neurons) (MSNs) in the striatum, the primary GABAergic output of the basal ganglia. These MSNs, which express GABA and substance P or enkephalin, are particularly vulnerable to mutant [huntingtin-protein](/proteins/huntingtin-protein) toxicity. This differential vulnerability produces the characteristic choreiform movements of HD [@reiner1988].

Mutant [huntingtin-protein](/proteins/htt-protein) disrupts GABAergic neurotransmission through:

Impaired GABA synthesis (reduced GAD expression)
Altered GABA_A receptor trafficking and surface expression
Disrupted mitochondrial function in MSNs
Excitotoxic injury from excessive corticostriatal [glutamate](/entities/glutamate) input

Parkinson's Disease

In [parkinsons](/diseases/parkinsons-disease), loss of [dopamine](/entities/dopamine) input to the striatum disrupts the balance between direct and indirect basal ganglia pathways, both of which involve GABAergic transmission from the striatum. The resulting disinhibition of the subthalamic nucleus and excessive output from the globus pallidus internus/[substantia-nigra](/brain-regions/substantia-nigra) pars reticulata produces the bradykinesia and rigidity characteristic of PD.

GABAergic dysfunction in PD also involves:

Altered GABAergic interneuron function in the [cortex](/brain-regions/cortex)
Changes in GABA_A and GABA_B receptor expression in the [basal-ganglia](/brain-regions/basal-ganglia)
GABAergic involvement in levodopa-induced dyskinesia

Amyotrophic Lateral Sclerosis

Cortical hyperexcitability is an early feature of [als](/diseases/amyotrophic-lateral-sclerosis), attributed in part to loss of GABAergic inhibition. Reduced cortical GABA levels, measured by magnetic resonance spectroscopy, correlate with disease progression and clinical disability.

Therapeutic Approaches Targeting GABA

Current Therapies

Benzodiazepines: GABA_A receptor positive allosteric modulators used for epilepsy and anxiety in neurodegenerative disease patients; concerns about cognitive side effects limit use in dementia
Vigabatrin: Irreversible GABA-T inhibitor that increases synaptic GABA; used in epilepsy
Baclofen: GABA_B agonist with potential neuroprotective properties
Tiagabine: GAT-1 inhibitor that prolongs GABAergic signaling

Emerging Therapeutic Strategies

α5-GABA_A receptor modulators: Negative allosteric modulators (inverse agonists) at α5-GABA_A receptors to reduce tonic inhibition and improve cognition in AD

MAO-B inhibitors for astrocytic GABA: KDS2010 and related compounds targeting reactive astrocyte-derived GABA overproduction; shown to reverse learning and memory impairment in AD mouse models [@jo2014]

Gamma entrainment: 40 Hz light and sound stimulation to restore gamma oscillations; in clinical trials for AD (GENUS study, MIT)

Interneuron transplantation: Preclinical studies transplanting GABAergic interneuron precursors (medial ganglionic eminence-derived) to restore inhibitory circuit function in AD models

GABA_B receptor modulators: Positive allosteric modulators with improved therapeutic windows compared to direct agonists [@cryan2021]

Gene therapy: AAV-mediated delivery of GAD genes to restore local GABA production; explored in [parkinsons](/diseases/parkinsons-disease) (AAV-GAD trial for subthalamic nucleus)

GABA as a Biomarker

GABA levels can be measured non-invasively using magnetic resonance spectroscopy (MRS), specifically the MEGA-PRESS (Mescher-Garwood Point Resolved Spectroscopy) technique. Studies have shown:

Reduced cortical GABA levels in [alzheimers](/diseases/alzheimers-disease), correlating with cognitive impairment
Decreased GABA in the [motor [cortex](/brain-regions/cortex)[/brain-regions/[motor-cortex](/brain-regions/motor-cortex) of ALS patients, predicting disease progression
Altered GABA/glutamate ratios in [huntington-pathway](/mechanisms/huntington-pathway) striatum
Potential utility of GABA MRS as a pharmacodynamic biomarker for GABAergic therapies in neurodegenerative disease
[Microglia](https://www.pnas.org/doi/10.1073/pnas.1204606109)](/genes/htt)

[Cryan JF, Kaupmann K. (2021). GABA B receptors in neurodegeneration. Trends in Pharmacological Sciences. [PubMed)](https://pubmed.ncbi.nlm.nih.gov/33728599/)

[Bhatt DK, et al. (2025). Hyperactivity of subicular parvalbumin interneurons drives early amyloid pathology and cognitive deficits in Alzheimer's Disease. Molecular Psychiatry. [Full text)](https://www.nature.com/articles/s41380-025-03217-4)

[Huh CYL, Bhatt DK, et al. (2022). Parvalbumin neuroplasticity compensates for somatostatin impairment, maintaining cognitive function in Alzheimer's Disease. Translational Neurodegeneration, 11, 26. [Full text)](https://translationalneurodegeneration.biomedcentral.com/articles/10.1186/s40035-022-00300-6)

[Targa Dias Anastacio H, et al. (2020). Histological characterization of interneurons in Alzheimer's Disease reveals a loss of somatostatin interneurons in the temporal [cortex](/brain-regions/cortex). Neuropathology and Applied Neurobiology. [PubMed)(https://pubmed.ncbi.nlm.nih.gov/32232904/)

[Xu Y, Bhati N, et al. (2020). GABAergic inhibitory interneuron deficits in Alzheimer's Disease: implications for treatment. Frontiers in Neuroscience, 14, 660. [Full text)(https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2020.00660/full)

[Amorim IS, et al. (2023). Factors affecting the GABAergic synapse function in Alzheimer's Disease: Focus on microRNAs. Ageing Research Reviews. [ScienceDirect)(https://www.sciencedirect.com/science/article/pii/S1568163723002829)

[Ali AB, Islam T, Bhatt DK. (2023). The fate of interneurons, GABAA receptor sub-types and perineuronal nets in Alzheimer's Disease. Brain Pathology, 33(4), e13129. [Wiley)](https://onlinelibrary.wiley.com/doi/10.1111/bpa.13129)

[--](/proteins/n--cadherin-protein)

External Links

[National Institute on Aging (NIA)](https://www.nia.nih.gov/health/alzheimers)
[Alzheimer's Association](https://www.alz.org/)
[Michael J. Fox Foundation for Parkinson's Research](https://www.michaeljfox.org/)
[ALS Association](https://www.als.org/)
[Cure Huntington's Disease Initiative (CHDI)](https://www.hdinsight.org/)
[National Institute of Neurological Disorders and Stroke (NINDS)](https://www.ninds.nih.gov/)

Background

The study of Gamma Aminobutyric Acid (Gaba) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Brain Atlas Resources

Allen Human Brain Atlas: [Gamma-Aminobutyric Acid expression search](https://human.brain-map.org/microarray/search/show?search_term=Gamma-Aminobutyric+Acid)
Allen Mouse Brain Atlas: [Gamma-Aminobutyric Acid search](https://mouse.brain-map.org/search/index.html?query=Gamma-Aminobutyric+Acid)
Allen Cell Type Atlas: [Transcriptomic cell type reference](https://portal.brain-map.org/atlases-and-data/rnaseq)
BrainSpan Developmental Transcriptome: [Gamma-Aminobutyric Acid developmental expression](https://www.brainspan.org/rnaseq/search/index.html?search_term=Gamma-Aminobutyric+Acid)

References

Siegel GJ, Agranoff BW, Albers RW, et al., Basic Neurochemistry: Molecular, Cellular and Medical Aspects (1999) (1999)

[Unknown, Mody I, GABA receptor deficit as a molecular mechanism linking excitation and inhibition imbalance in Alzheimer's Disease (2021) (2021)](https://doi.org/10.1016/j.phrs.2020.105314)

[Unknown, Schwarcz R, Multiple GABA systems in Alzheimer's Disease brain (2021) (2021)](https://doi.org/10.3390/ijms222111677)

[Jo S, et al., Astrocytic GABA release is a novel therapeutic target for Alzheimer's Disease (2014) (2014)](https://doi.org/10.1038/nature37531)

[Unknown, Rudolph U, Mohler H, GABA A receptor subtypes: a new pharmacology (2004) (2004)](https://doi.org/10.1016/j.tips.2004.09.004)

[Unknown, Cryan JF, Kaupmann K, GABA B receptors in neurodegeneration (2021) (2021)](https://doi.org/10.1016/j.tips.2021.01.003)

[Bhatt DK, et al., Hyperactivity of subicular parvalbumin interneurons drives early amyloid pathology and cognitive deficits in Alzheimer's Disease (2025) (2025)](https://doi.org/10.1038/s41380-025-03217-4)

[Huh CYL, Bhatt DK, et al., Parvalbumin neuroplasticity compensates for somatostatin impairment, maintaining cognitive function in Alzheimer's Disease (2022) (2022)](https://doi.org/10.1186/s40035-022-00300-6)

[Targa Dias Anastacio H, et al., Histological characterization of interneurons in Alzheimer's Disease reveals a loss of somatostatin interneurons in the temporal cortex (2022) (2022)](https://doi.org/10.1111/bpa.13059)

[Unknown, Palop JJ, Mucke L, Epilepsy and cognitive impairment in Alzheimer's Disease (2010) (2010)](https://doi.org/10.1001/archneurol.2009.237)

[Iaccarino HF, et al., Gamma frequency entrainment attenuates amyloid load and modifies microglia (2016) (2016)](https://doi.org/10.1038/nature20587)

[Reiner A, et al., Differential loss of striatal projection neurons in Huntington's Disease (1988) (1988)](https://doi.org/10.1073/pnas.85.15.5733)

📖 View canonical wiki page →

Related Entities

entities-gaba

▸Metadataorigin_type: v1_polymorphic_backfill

slug	entities-gaba
kg_node_id	None
entity_type	entity
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-04bd9dc7fc83
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'entities-gaba'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

85%

Debates

0

Incoming

17

Outgoing

17

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Gamma-Aminobutyric Acid (GABA)

Introduction

Overview

Introduction

Overview

Synthesis and Metabolism

Biosynthesis

Vesicular Transport and Release

Reuptake and Degradation

GABA Receptors

GABA_A Receptors (Ionotropic)

GABA_B Receptors (Metabotropic)

GABA_C Receptors

GABAergic Interneurons in the Brain

Parvalbumin (PV) Interneurons

Somatostatin (SST) Interneurons

Vasoactive Intestinal Peptide (VIP) Interneurons

Neuropeptide Y (NPY) and Cholecystokinin (CCK) Interneurons

Role in Neurodegenerative Diseases

Alzheimer's Disease

Huntington's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis

Therapeutic Approaches Targeting GABA

Current Therapies

Emerging Therapeutic Strategies

GABA as a Biomarker

External Links

Background

Brain Atlas Resources

References

💬 Discussion